The effect of hypoxia on PD-L1 expression in bladder cancer

Vicky Smith1*, Debayan Mukherjee1, Sapna Lunj1, Ananya Choudhury1,2,3, Peter Hoskin1,2,3, Catharine West1 and Tim Illidge1,2,3

Abstract

Introduction: Recent data has demonstrated that hypoxia drives an immunosuppressive tumour microenvironment (TME) via various mechanisms including hypoxia inducible factor (HIF)-dependent upregulation of programmed death ligand 1 (PD-L1). Both hypoxia and an immunosuppressive TME are targetable independent negative prognostic factors for bladder cancer. Therefore we sought to investigate whether hypoxia is associated with upregulation of PD-L1 in the disease.

Materials and methods: Three human muscle-invasive bladder cancer cell lines (T24, J82, UMUC3) were cultured in normoxia (20% oxygen) or hypoxia (1 and 0.1% oxygen) for 24 h. Differences in PD-L1 expression were measured using Western blotting, quantitative polymerase chain reaction (qPCR) and flow cytometry (≥3 independent experiments). Statistical tests performed were unpaired t tests and ANOVA. For in silico work an hypoxia signature was used to apply hypoxia scores to muscle-invasive bladder cancers from a clinical trial (BCON; n = 142) and TCGA (n = 404). Analyses were carried out using R and RStudio and statistical tests performed were linear models and one-way ANOVA.

Results: When T24 cells were seeded at < 70% confluence, there was decreased PD-L1 protein (p = 0.009) and mRNA (p < 0.001) expression after culture in 0.1% oxygen. PD-L1 protein expression decreased in both 0.1% oxygen and 1% oxygen in a panel of muscle-invasive bladder cancer cells: T24 (p = 0.009 and 0.001), J82 (p = 0.008 and 0.013) and UMUC3 (p = 0.003 and 0.289). Increasing seeding density decreased PD-L1 protein (p < 0.001) and mRNA (p = 0.001) expression in T24 cells grown in both 20 and 1% oxygen. Only when cells were 100% confluent, were PD-L1 protein and mRNA levels higher in 1% versus 20% oxygen (p = 0.056 and p = 0.037). In silico analyses showed a positive correlation between hypoxia signature scores and PD-L1 expression in both BCON (p = 0.003) and TCGA (p < 0.001) cohorts, and between hypoxia and IFNγ signature scores (p < 0.001 for both).

Conclusion: Tumour hypoxia correlates with increased PD-L1 expression in patient derived bladder cancer tumours. In vitro PD-L1 expression was affected by cell density and decreased PD-L1 expression was observed after culture in hypoxia in muscle-invasive bladder cancer cell lines. As cell density has such an important effect on PD-L1 expression, it should be considered when investigating PD-L1 expression in vitro.

Keywords: hypoxia, HIF, PD-L1, Tumour microenvironment, Immunosuppression, TIME, Cell density, Bladder cancer, MIBC

*Correspondence: victoria.smith-15@postgrad.manchester.ac.uk
1 Division of Cancer Sciences, University of Manchester, M20 4BX Manchester, UK
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
are classified as muscle-invasive bladder cancer (MIBC) for which the five-year survival rates are 45, 40 and 10% respectively [2].

The two definitive treatment approaches for MIBC are cystectomy, or radiotherapy with a radiosensitiser. Neo-adjuvant chemotherapy can be given with either, but has a limited contribution to improved survival [3]. Immunotherapy for bladder cancer has an extensive history, with the first immunotherapy (Bacillus Calmette–Guérin) for non-MIBC being approved in 1990 [4]. In the last 5 years, six new immunotherapies were approved for advanced urothelial carcinoma, most targeting the PD-1/PD-L1 pathway. However, despite initial successes the rates of durable responses remain low with generally only around one in five patients showing a sustained response [5].

An immunosuppressive tumour microenvironment (TME) is known to be a negative prognostic factor contributing to recurrence of disease and tumour progression [6]. Hypoxia is a common feature of many solid tumours and is also an adverse prognostic factor in bladder cancer [7, 8]. Both an immunosuppressive TME and hypoxia contribute to the failure of radiotherapy [9, 10]. Therefore, the relationship between immunosuppression and hypoxia is of interest when developing biomarkers to guide the management of bladder cancer.

Hypoxia inducible factor (HIF1)-1α is a transcription factor that regulates a plethora of genes in response to decreased oxygen availability [11]. Recently, it was shown that hypoxia-induced gene changes affect tumour immune responses and contribute towards an immunosuppressive TME [12]. The mechanisms involved include direct effects on immune cells that alter their functions and indirect effects due to altered cytokine and chemokine expression that impact the recruitment and migration of immune cells [13, 14].

Specifically, hypoxia via HIF1α was shown to increase expression of the immune checkpoint gene programmed death - ligand 1 (PD-L1) in human and mouse cancer cell lines [15, 16]. The effect of hypoxia on PD-L1 expression in bladder cancer cells has not previously been reported.

Here we aimed to investigate the effects of hypoxia on PD-L1 expression in bladder cancer using in vitro and in silico approaches.

### Materials and methods

**Cell lines**

Human MIBC cell lines (T24, J82, UMUC3) were cultured in Eagle’s Minimum Essential Media (Gibco; ThermoFisher Scientific, Loughborough, UK) supplemented with 10% foetal bovine serum (Gibco) and L-glutamine (2 mM; Gibco). Cell lines were authenticated by the Cancer Research UK Manchester Institute core facilities services every 6 months and tested for mycoplasma monthly.

**Exposure to hypoxia**

Cells were seeded at a density of $1 \times 10^5$ per well, unless otherwise stated, onto 6-well cell culture plates (Corning™ Costar™, Leicestershire, UK) in a humidified atmosphere of air plus 5% CO$_2$ (here termed normoxia) and left to adhere for 24 h. Some plates were then transferred to a hypoxia cabinet (Baker-Ruskin®, Bridgend, Wales), washed with phosphate buffered saline (PBS; made by in-house services) and fresh media added. Both the PBS and fresh media were pre-equilibrated to the required oxygen concentration for 24 h. The other plates were processed in the same way but in normoxia.

**Treating cells with pharmacological agents**

Human recombinant interferon gamma (IFNγ) (Peprotech, London, UK) was reconstituted in dimethyl sulfoxide (DMSO) to make a working stock solution of 20 μg/ml. It was added directly to media culture at the same point of processing as described above to a working concentration of 10 ng/ml.

**Western blotting**

Cells were lysed in situ by adding lysis buffer solution (Cell Signalling Technology, London, UK) and protease inhibitor cocktail (Cell Signalling Technology) and placing on ice for 10 min. Samples were then sonicated at 10 amplitude microns for 10 s using a Soniprep 150 (Measuring and Scientific Equipment, London, UK) before centrifugation at 14,000 G for 15 min. Protein concentrations of the lysates were measured using a BCA Protein Assay kit (ThermoFisher Scientific, Loughborough, UK), and the solution resolved on 4–20% Tris-Glycine Protein Gels (ThermoFisher Scientific) prior to transferring to a nitrocellulose membrane (Bio-Rad, Watford, UK). The membrane was then incubated with the primary and secondary antibodies with PBS washes in between. Table 1 lists antibody suppliers and concentrations.

### Table 1 Concentrations and supplier information of antibodies used for Western blotting

| Target | Raised in | Dilution | Supplier Code |
|--------|-----------|----------|---------------|
| PD-L1  | Rabbit    | 1:2000   | 13,684        |
| HIF1α  | Mouse     | 1:500    | 610,959       |
| GAPDH  | Rabbit    | 1:2500   | 2118          |
| Mouse-HRP | Goat    | 1:7500  | 62–6520       |
| Rabbit-HRP | Goat    | 1:5000  | 65–6120       |

*Note: Supplier information includes the antibody code and concentration used for Western blotting.*
Real-time PCR
RNA was extracted using a Qiagen RNeasy Mini Kit according to the manufacturer’s protocol and quantified using a NanoDrop™ (ThermoFisher Scientific). cDNA was obtained using OmniScript RT Kit (Qiagen, Manchester, UK) with random hexamer primers (ThermoFisher Scientific) and RNase Inhibitor (New England Biolabs, Hitchin, UK). Primers were designed by Primer-BLAST and Primer3 software, checked using Beacon Design Software (Premier Biosoft) and made by Eurofins Genomics (Ebersberg, Germany) before being resuspended in Tris – EDTA (TE) buffer. Table 2 lists primer sequences. Serial dilutions of primers were used for validation experiments and primer mixes were made with SYBR Green Master Mix (ThermoFisher Scientific). 384-well PCR plates were run using a QuantStudio 5 Real-Time PCR System and appropriate controls.

Flow cytometry
Cells were trypsinised, placed in fluorescence-activated cell sorting (FACS) tubes (Corning, Flintshire, UK), washed in FACS buffer (1% FBS in PBS), centrifuged and resuspended in a series of solutions with FACS buffer washing steps in between. In order, the cells were resuspended in a live/dead fixable cell stain (1:1000; Invitrogen; ThermoFisher Scientific), human FcR blocking solution (1:100; Miltenyi Biotec, Woking, UK), then either PD-L1 PE antibody (1:100; Invitrogen) or control PE mouse IgG1 k isotype antibody (1:100) (BD Pharmigen, CA, USA) before being fixed in 1% paraformaldehyde. Samples were acquired on a LSRII flow cytometer (BD Biosciences, CA, USA) with 10,000 viable cells collected per sample. Flow cytometry was performed in either duplicate or triplicate wells as stated and each well was split into two FACS tubes for immunoglobulin control alongside target of interest. The data collected were then processed using FlowJo software (version 10.6.1). Table 3 lists reagent details.

Bioinformatics
BCON is a clinical trial registered as CRUK/01/003 of which the details and conclusions are outlined in the initial findings report [17]. Gene expression data from the BCON cohort were obtained as previously described [18] and the TCGA-BLCA data were obtained using the R packages “TCGAUtils” and “curatedTCGAData”. Both datasets were filtered to include only tumours of a known stage and stage 2 and above. Analyses were carried out using R (version 4.0.3) and RStudio (version 1.3).

Statistical analysis
In vitro data were tested by unpaired t test or ANOVA using GraphPad Prism 8 software. In silico data were tested by linear regression, Pearson’s correlation and ANOVA using R and RStudio.

Results
Hypoxia decreases expression of PD-L1 in T24 human bladder cancer cells
To investigate the effects of hypoxia on PD-L1 expression in T24 MIBC cells they were cultured at 0.1% oxygen and 20% oxygen and the differences in PD-L1 expression examined. PD-L1 expression significantly decreased in hypoxia (0.1% oxygen for 24 h) at both the RNA (qPCR) and protein (Western blotting, flow cytometry) level in T24 human bladder cancer cells (Fig. 1). IFNγ is a known stimulant of PD-L1 and its addition led to the expected stimulation of PD-L1 [19]. However, when IFNγ stimulated cells were cultured in hypoxia, the IFNγ-driven PD-L1 increase was reduced (Fig. 1). This finding further highlights the negating effects of hypoxia on PD-L1 expression in T24 cells. HIFα protein expression was present in all the samples cultured in hypoxia (0.1% oxygen) and absent in those under normoxia, confirming the cells are responding to the hypoxic conditions (Supplementary Fig. 1). Comparison of the proportion of viable

| Primer   | Sequence         | Tm (°C) | GC-content (%) |
|----------|------------------|---------|---------------|
| PD-L1 forward | TATGGTGTTGCCGACTACA | 57.3    | 50            |
| PD-L1 reverse  | TGCGTCCAGAATTACAGA | 57.3    | 50            |
| SDHA forward   | CATCCACTACATGCAGGCA | 59.8    | 52.4          |
| SDHA reverse    | ATCTTGCCATCTTCAGTCTGCTA | 59.3    | 41.7          |

| Name            | Details                               | Dilution | Supplier         | Code   |
|-----------------|---------------------------------------|----------|------------------|--------|
| Live/dead stain | Diluted in PBS                         | 1:1000   | Invitrogen       | L34973 |
| Fc blocking     | Diluted in FACS buffer                 | 1:100    | Miltenyi Biotec  | 130-059-901 |
| PD-L1 antibody  | PE conjugated                          | 1:100    | Fisher Scientific| 12-5983-41 |
| IgG antibody    | PE conjugated                          | 1:100    | BD Pharmigen     | 554,121 |
cells between samples showed hypoxia did not induce excessive cell death (Supplementary Fig. 2).

Both 0.1 and 1% hypoxia decreases PD-L1 expression in a panel of human muscle-invasive bladder cancer cells. To investigate whether the decrease in PD-L1 might be cell line or oxygen concentration dependent, we investigated two other human MIBC cell lines (J82 and UMUC3) and a less severe level of hypoxia (1% oxygen). There was a consistent significant decrease in PD-L1 protein expression after exposure to hypoxia in all three bladder cancer cell lines and at both 0.1 and 1% oxygen concentrations (Fig. 2). Across the three cell lines there was also a continued attenuation of the IFNγ-driven PD-L1 induction in hypoxia.
PD-L1 levels decrease as cell density increases and a PD-L1 increase in hypoxia occurs only when cells are highly confluent

The effects of cell density on hypoxia-induced changes in PD-L1 expression were explored in T24 cells. This cell line was used due to its fast proliferation rate, with a doubling time of around 20 h [20, 21], which facilitated the assessment of increasing cell density. As we showed similar effects in both 0.1 and 1% hypoxia we took forward the less severe 1% hypoxia for further experiments to minimise stress on the cells. Density gradient experiments showed PD-L1 protein and mRNA expression decreased significantly with increasing cell density in both normoxia and hypoxia (Fig. 3). A significant hypoxia-induced increase in PD-L1 expression was only seen when the cells were seeded at the highest densities (Fig. 3). Increasing cell density had no effect on viability (Supplementary Fig. 3).

PD-L1 gene expression correlates positively with hypoxia in muscle-invasive bladder cancer patients

To elucidate further the potential relationship and clinical relevance between hypoxia and PD-L1, in silico analyses were performed using gene expression datasets from two bladder cancer cohorts. A bladder cancer specific hypoxia signature previously published was used to assign hypoxia scores, which were then correlated with the expression of PD-L1 (CD274) [18]. A significant positive correlation was seen between hypoxia signature scores and the expression of PD-L1 in both cohorts (Fig. 4A, B). The median hypoxic score across each cohort stratified patients into low and high hypoxia groups. In both cohorts, the high hypoxia tumours had a significantly higher expression of PD-L1 compared with low hypoxia tumours (Fig. 4C, D).

Hypoxia and IFNγ-signalling signature scores correlate positively in muscle-invasive bladder cancer patients

Finally, a published IFNγ gene signature representing extent of IFNγ signalling was used to attribute IFNγ scores to the BCON and TCGA cohorts [22]. There were positive correlations between hypoxia and IFNγ signature scores (Fig. 5A, B). The tumours were again stratified into low and high hypoxia and in both cohorts the high hypoxia tumours showed significantly higher IFNy scores compared with the low hypoxia tumours (Fig. 5C, D).

Discussion

Several findings emerged from this study. First, hypoxia decreased PD-L1 expression and abrogated IFNγ-induced increases in PD-L1 in bladder cancer cells. Second, PD-L1 expression decreased with increasing cell seeding density, which was pronounced in cells cultured in normoxia versus hypoxia. Third, a hypoxia-induced increase in PD-L1 was only seen with the highest cell seeding densities when there was a marked down-regulation of PD-L1 in cells grown in normoxia. Fourth, PD-L1 gene expression, as well as IFNγ-signalling expression, correlated positively with hypoxia in bladder cancers in silico.

The observation that hypoxia decreases PD-L1 expression initially appears to conflict with conclusions made in published literature. Noman et al. [16] concluded that hypoxia induced an upregulation of PD-L1 in a panel of murine and human cell lines. However, the finding appears to be tissue-type specific as only one (B16-F10) of four murine cell lines (B16-F10 melanoma; LLC lung; CT26 colon; 4 T1 mammary) studied showed an increase in the percentage of PD-L1 positive cells after culture in 0.1% oxygen. There was a minimal increase at 72 h in the lung, no change in the colon, and a non-significant decrease in the mammary cell line. In the human cell lines, there was a marked hypoxia-induced increase in PD-L1 in melanoma (T1, M4T), a small significant increase in lung (IGR-Heu), and no change in breast (MCF-7). In addition, all the hypoxia results (24h, 48h, 72h) were compared with 72 h normoxia data. Interestingly, across the cell lines, there were no significant changes observed at 24h, except for the murine melanoma cell line, and most of the significant changes were seen at the 72 h time-point. As cell density will increase at the later time-point, the results might be affected by the cell density effect we found here.

Barsoum et al. [15] also reported hypoxia-induced upregulation of PD-L1 expression. They incubated cells in 0.5% oxygen for 24 h and showed an increase in PD-L1 expression in human prostate (DU145) and breast (MDA-MB-231) cancer cells. The authors stated that all their experiments were conducted using cultures that did
Fig. 2 (See legend on previous page.)
not exceed 70% confluence. The study also used siRNA knockdown experiments to show that PD-L1 upregulation was HIF1α dependent. HIFs bind to gene promoter regions known as hypoxia response elements (HREs). In 2011, Schödel et al. used chromatin immunoprecipitation sequencing (ChIPseq) to perform high resolution mapping of HIF binding sites in MCF-7 cells; PD-L1 was not in their 300+ list of high stringency HIF1 and HIF2 binding sites [23]. Given that Noman et al. also saw no effect of hypoxia on the expression of PD-L1 in MCF-7 cells, but Barsoum et al. identified HREs in the PD-L1 gene in DU145 cell lines as well as an hypoxia-induced increase in PD-L1 expression, it is possible that the hypoxia-induced upregulation of PD-L1 is tissue specific [15, 16]. To our knowledge this is the first documentation of the effects of hypoxia on PD-L1 expression in bladder cancer cell lines. The current literature outlines a discrepancy between the effects of hypoxia on the expression of PD-L1 across cell lines of different tissue origins and further comprehensive characterisation across an extensive panel of other cancer cell lines is required for more definitive conclusions.

Hypoxic cells preserve energy by reducing metabolic processes via HIF regulation of various genes [11]. Decreases in cellular metabolism also occur as a result of increasing cell density, and a recently published report underlines the importance of considering cell density in in vitro experiments and how cell density affects cellular metabolic changes [24, 25]. Therefore, the PD-L1 decrease we found in cells cultured in hypoxia could be due to reduced cellular metabolism. Furthermore, cells proliferate faster in normoxia than in hypoxia due to having higher cellular metabolism. Therefore, in the highly dense cells, a cell density-mediated reduction in metabolism should occur faster and be more pronounced in normoxia. The observed effect, therefore, might be an abrogated decreased PD-L1 expression occurring in the densely packed hypoxic conditions, rather than a true cellular hypoxia-driven increase and warrants further investigation. In support of this suggestion, several publications showed that increasing cell density results in decreased expression of cell surface markers including transforming growth factor beta (TGF-b) receptor in fibroblast cells, epidermal growth factor receptors (EGFRs) in breast cancer cells, and tumour necrosis factor (TNF) receptors in HeLa epithelial and myeloid HL-60 cell lines [26–28].

Increasing cell density leads to contact inhibition and cell cycle arrest via the Hippo/YAP pathway [29], and interacts with multiple intracellular signalling pathways.
[30–32] that regulate cyclin D expression [33]. PD-L1 expression is also affected directly by the cell cycle via cyclin D regulation [34] and via interactions with multiple cell signalling pathways, e.g., via PI3K/AKT, JAK/STAT3, WNT, NFkB and MAPK [35, 36]. This complex interplay between cell density, cell cycle, cell signalling and PD-L1 expression is yet to be fully elucidated and more research is needed to understand how hypoxia affects the interactions. Although we showed cell density affects the expression of PD-L1, we have not identified whether it is a direct effect, or due to cell density-mediated changes in cell cycle or cell signalling. The discrepancy in some of the in vitro results could potentially be explained by further investigations into the cell cycle and cell signalling pathways to determine how these affect the changes in PD-L1 expression in response to hypoxia.

To further explore the relationship between hypoxia and PD-L1 beyond the in vitro cell culture experiments we performed in silico analyses in patient tumours. The BCON trial randomised patients to receive either radiotherapy or radiotherapy plus hypoxia-modifying carbogen and nicotinamide (CON). TCGA-BLCA is a cohort

![In silico analyses show a positive association between hypoxia and PD-L1 in muscle-invasive bladder tumours. Analyses involved microarray data from the BCON trial normalised previously using aroma package and filtered to include only tumours stage 2 and above (n = 142) and the TCGA-BLCA RNAseq2GeneNorm dataset downloaded using the Bioconductor package TCGAutils and filtered to include only tumours of a known stage 2 and above (n = 404). Hypoxia scores were applied to each tumour sample using a previously published 24-gene bladder cancer hypoxia signature. Hypoxia signature scores were plotted against the expression of PD-L1 in A) BCON and C) TCGA cohorts. R² values were calculated using Pearson’s correlation coefficient and the p values represent a linear model analysis. Tumours were stratified into hypoxia low or high using the median of the hypoxia scores for each cohort, and plotted against the PD-L1 expression in the B) BCON and D) TCGA cohorts. P values were calculated using one way ANOVA between the two groups. p values are represented as follows: ns = not significant, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001]
of bladder cancer patients who underwent surgery and the gene expression dataset from these tumours is publicly available. The positive correlations seen between hypoxia signature scores and PD-L1 expression in both cohorts indicates that, despite our cell line findings, there is a relationship between the extent of hypoxia and increased PD-L1 expression in bladder cancer. This has implications for the treatment of MIBC whereby some patients may potentially benefit from a combination of hypoxia-modifying therapy with immunotherapy agents. In the same cohorts, we saw a positive correlation between hypoxia and IFNγ-signalling signature scores. IFNγ is known to stimulate PD-L1 and increased PD-L1 expression in the more hypoxic tumours could be a direct result of increased IFNγ signalling [19]. Current in silico investigations have shown more immune infiltrates present as tumour hypoxia increases. As IFNγ is a central immune signalling molecule that is produced by many immune infiltrates, this provides an explanation for the increased IFNγ-signalling in the more hypoxic tumours. This suggestion needs investigating further. Taken together, our in vitro and in silico findings show that, although hypoxia-mediated cellular PD-L1 upregulation is not seen in bladder cancer cell lines, there is an overall increased expression of PD-L1 as tumour hypoxia increases in bladder cancer, which could be a result of

---

**Fig. 5** In silico analyses show a positive association between hypoxia and IFNγ-signalling in muscle-invasive bladder tumours. Hypoxia scores were applied to tumours from BCON and TCGA cohorts filtered to include stage 2 and above only. A published 6-gene IFNγ gene signature was used to attribute an IFNγ score to each tumour. These scores were plotted against the hypoxia scores in the A) BCON and C) TCGA cohorts. R² values were calculated using Pearson’s correlation coefficient and the p values represent a linear model analysis. Tumours were stratified into hypoxia low or high using the median of the hypoxia score from each cohort, and plotted against the IFNγ signature score in the B) BCON and D) TCGA cohorts. P values were calculated using one way ANOVA between the two groups. p values are represented as follows: ns = not significant, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001
increased IFNγ-signalling in the more hypoxic TMEs leading to an increased PD-L1 expression. These results highlight the importance of including patient sample analysis alongside cell line work when investigating immune-related contexts to provide translatable findings that account for the immune tumour microenvironment.

Conclusions
In conclusion, we report for the first time that in bladder cancer cells the in vitro cell density affects PD-L1 expression in contrast to an absence of hypoxia-induced increase in PD-L1 expression. These findings underlie both the importance of cell density on the expression of PD-L1 in vitro and the need to address and document this in further publications. Our clinical data provide evidence that hypoxia may induce an immunosuppressive TME in bladder cancer and highlight the importance of further studies to investigate the underlying mechanisms.

Supplementary Information
The online version contains supplementary material available at [https://doi.org/10.1186/s12885-021-09009-7](https://doi.org/10.1186/s12885-021-09009-7).

Additional file 1: Supplementary Figure 1. HIF1a is present in T24 cells cultured in hypoxia and absent when cultured in normoxia. Western blot showing the presence/absence of HIF1a across different experimental conditions alongside the changes in PD-L1 expression. GAPDH was used as an experimental loading control. Independent experiments were performed three times and a representative blot is shown.

Additional file 2: Supplementary Figure 2. Hypoxia does not induce excessive cell death in T24 cells. Flow cytometry shows there is no excessive cell death induced by culture in 0.1% O2. A live/dead stain was incorporated into the assay, which only enters cells with compromised membranes. Gating around cells with no dye uptake and comparing with total population allows for the analysis of the proportion of viable cells. Data are the mean ± standard error of the mean (SEM) from at least three independent experiments performed in duplicates, of which each sample had 10,000 viable cells analysed.

Additional file 3: Supplementary Figure 3. Increased cell seeding density does not induce excessive cell death in T24 cells. Flow cytometry shows no increase in cell death neither by culture in 0.1% O2 nor as the cell seeding density increases. A live/dead stain was incorporated into the assay, which only enters cells with compromised membranes. Gating around cells with no dye present and comparing with total population allows for the analysis of the proportion of viable cells. Data are the mean ± standard error of the mean (SEM) from at least three independent experiments performed in duplicates, with 10,000 viable cells analysed per sample.

Additional file 4: Supplementary Figure 4. Tabulated data from the graphs shown in Fig. 2. This table shows the averages of normalised flow cytometry results comparing changes in PD-L1 expression across various experimental conditions.

Additional file 5: Supplementary Figure 5. Full length original and unprocessed Western blots shown in Fig. 1A. Western blot showing the presence/absence of A) PD-L1 and B) GAPDH across different experimental conditions. GAPDH was used as an experimental loading control. Independent experiments were performed at least three times and a representative blot is shown.

Additional file 6: Supplementary Figure 6. Full length original and unprocessed Western blots shown in Supplementary Fig. 1. Western blot showing the presence/absence of A) HIF1a, B) PD-L1 and C) GAPDH across different experimental conditions. GAPDH was used as an experimental loading control. Independent experiments were performed at least three times and a representative blot is shown.

Acknowledgements
VS, AC, CW, PH and TI are all supported by the NIHR Manchester BRC. Hitesh Mistry provided support and guidance with statistical tests. CRUK MI Molecular Biology Core Facilities provided support and use of equipment. Targeted Therapies Group led by TI and Translational Radiobiology group co-led by CW and AC both contributed to helpful discussions throughout the project.

Authors’ contributions
VS generated all in vitro data, performed all in silico analysis and wrote the manuscript. SL and DM provided support for data interpretation and analysis. PH provided BCON dataset. AC provided bladder cancer and hypoxia expertise. CW was a major contributor to the manuscript and study design. TI led the study and supported the work. The authors read and approved the final manuscript.

Funding
The work was funded by the NIHR Manchester Biomedical Research Centre. The funding body had no role in the design of the study, interpretation of data or writing of the manuscript but provided the cost of consumables for the study and provided a stipend for the corresponding author.

Availability of data and materials
All raw data from in vitro experiments as well as further data supporting the chosen representative image presented in this published article and its supplementary files can be made available from the corresponding author on request. The TCGA-BLCA gene expression data are publically available and were obtained using the R package “curatedTCGADatasets” to download the RNASeq2GeneNorm assay from the disease code BLCA (BLCA_RNASeq2GeneNorm-20160128). The BCON clinical data are not publically available and belong to Peter Hoskin of the University of Manchester, who is to be contacted for the data to be made available on reasonable request.

Declarations

Ethics approval and consent to participate
The BCON study was previously conducted according to ethics declared in the relevant published paper (LREC 09/H1013/24) [17]. The expression data are available for use within the group under these ethics approvals.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Cancer Sciences, University of Manchester, M20 4BX Manchester, UK. 2 The Christie NHS Foundation Trust, Manchester, UK. 3 Manchester Academic Health Science Centre, Manchester, UK.

Received: 19 May 2021 Accepted: 9 November 2021

Published online: 25 November 2021

References
1. Cancer Research UK. Bladder cancer mortality statistics. Available from: [https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer/mortality]. [cited 5 Jul 2020]
2. Office for National Statistics. Cancer survival in England - adults diagnosed. Available from: [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancer survivaratescancersurvivalenglandadultsdiaognosed]. [cited 8 Jul 2020]
3. Song YP, McWilliam A, Hoskin PJ, Choudhury A. Organ preservation in bladder cancer: an opportunity for truly personalized treatment. Nat Rev Urol. 2019;16(9):S11–S22. Available from: www.nature.com/nrurol. Nature Publishing Group (cited 30 Apr 2021).

4. Morales A, Eldinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976. J Urol. 2002;167(2 Pt 2):891–4.

5. Wolczewicz M, Hrynkiwecz R, Grywaliska E, Suchojad T, Lekowski T, Rolinski J, et al. Immunotherapy in bladder cancer: Current methods and future perspectives. Cancers (Basel). 2020;12(5). Available from: /pmc/articles/PMC7281703/. (cited 30 Apr 2021).

6. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646–674. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21376230. (cited 15 Oct 2018).

7. Theodoropoulos VE, Lazaris AC, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, et al. Hypoxia-Inducible Factor 1a Expression Correlates with Angiogenesis and Unfavorable Prognosis in Bladder Cancer. Eur Urol. 2004;46(2):200–208. Available from: https://www.sciencedirect.com/science/article/pii/S0302283800017691?via%3Dihub (cited 1 Oct 2019).

8. Chai CY, Chen W-T, Hung W-C, Kang W-Y, Huang Y-C, Su Y-C, et al. Hypoxia-inducible factor-1a expression correlates with focal macrophage infiltration, angiogenesis and unfavorable prognosis in uterine cervical carcinoma. J Clin Pathol. 2008;61(5):658–664. Available from: https://jcp.bmj.com/content/61/5/658 (cited 1 Oct 2019).

9. Höckel M, Schlenger K, Mitze M, Schäffer U, Vaupel P. Hypoxia and angiogenesis in head and neck cancer. Cancer Metastasis Rev. 2001;20(3):191–209. Available from: https://link.springer.com/article/10.1023/A:1013861120200 (cited 18 Feb 2018).

10. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment. Nat Rev Cancer. 2015.

11. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular responses. Oncologist 2004;9 Suppl 5:4–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15591417 (cited 3 Dec 2018).

12. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646–674. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21376230. (cited 15 Oct 2018).

13. Murdoch C, Giannoudis A, Lewis CE, Weich HA, Mantovani A, Marmé D. Hypoxia: A Double-Edged Sword in Cancer Therapy. Cancer Invest. 2016;34(10):536–545. Available from: https://pubmed.ncbi.nlm.nih.gov/27879800/ (cited 24 Sep 2021).

14. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319524/ (cited 24 Sep 2021).

15. Masters JRW, Hepburn PJ, Walker L, Highman WJ, Treadosiewicz UK, Povey S, et al. Tissue Culture Model of Transitional Cell Carcinoma: Characterization of Twenty-two Human Urothelial Cell Lines. Cancer Res. 1986;46:3630–6.

16. Ayer M, Lunecford J, Nebozyn M, Murphy E, Loboda A, Kaufman DR, et al. IFNγ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40.

17. Schödel J, Okonkopomoupolos S, Ragoussis J, Pugh CW, Ractcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by Chip-seq. Blood. 2011;117(23):e207–007.

18. Trajkovic K, Valdez C, Yssellstein D, Krain D. Fluctuations in cell density alter protein markers of multiple cellular compartments, confounding experimental outcomes. PLoS One. 2019;14(2). Available from: https://pubmed.ncbi.nlm.nih.gov/30716115/ (cited 28 Nov 2020).

19. Wright Muelas M, Ortega F, Breitling R, Bendsen C, Westerhoff H V. Rational cell culture optimization enhances experimental reproducibility in cancer cells. Sci Rep. 2018;8(1):1–16. Available from: www.nature.com/scientificreports/ (cited 24 Mar 2021).

20. Petridou S, Matlabova O, Spanakis S, Masur SK. TGF-beta receptor expression and smad2 localization are cell density dependent in fibroblasts. Invest Ophthalmol Vis Sci. 2000;41(1):89–95.

21. Kuzevski CA, Miller KA, Rizzino A. Influence of cell density and receptor number on the binding and distribution of cell surface epithelial growth factor receptors. Vitr Cell Dev Biol - Anim J Soc Vitr Biol. 1993;29(9):706–713. Available from: https://link.springer.com/article/10.1007/BF02631427 (cited 18 Feb 2018).

22. Polcik E, Milhalk R, Ali-Osman F, Aggarwal BB. Cell density-dependent regulation of cell surface expression of two types of human tumor necrosis factor receptors and its effect on cellular response. J Cell Biochem. 1994;54(4):453–464. Available from: http://doi.wiley.com/10.1002/jcb.240540412 (cited 1 Feb 2021).

23. Gérard C, Goldbeter A. The balance between cell cycle arrest and cell proliferation: control by the extracellular matrix and by contact inhibition. Interface Focus. 2014. Available from: https://royalsocietypublishing. org/doi/abs/10.1098/rsfs.2013.0075 (cited 24 Sep 2021).

24. Pavel M, Renna M, Park SJ, Menzies FM, Ricketts T, Fullgrabe J, et al. Contact inhibition controls cell survival and proliferation via YAP/TAZ-autophagy axis. Nat Commun 2018;9(1):1–18. Available from: https://www.nature.com/articles/s41467-018-05388-x (cited 24 Sep 2021).

25. Lallemand D, Ham J, Garbay S, Bakiri L, Traincard F, Jeannequin O, et al. PI3K protein level regulates PI3K-AKT pathway activity in cell populations. Curr Biol. 2011;21(3):173. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394538/ (cited 24 Sep 2021).

26. Doktorova RJ, Xiong Y. Signaling Pathways that Control Cell Proliferation. Cold Spring Harb Perspect Biol. 2013;5(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578363/ (cited 24 Sep 2021).

27. Zhang J, Bu X, Wang H, Zhu Y, Nihira NT, Geng Y, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170890/ (cited 24 Sep 2021).

28. Yuan TL, Wulf G, Burga L, Cantley LC. Cell-to-cell variability in P13K protein level regulates PI3K-AKT pathway activity in cell populations. Curr Biol. 2011;21(3):173. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394538/ (cited 24 Sep 2021).

29. Shexin X, Zhaowei Z, Li L, Li Y, Wang X, Xu Z. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol. 2019;10:529. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571691/ (cited 24 Sep 2021).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.